Skip to main content
SpringerLink
Log in

Postoperative Surveillance for Recurrent Malignant Disease

  • Chapter
  • First Online:
Surgery of the Thyroid and Parathyroid Glands

  • 2365 Accesses

Abstract

The goals of initial therapy for thyroid cancer are to remove or destroy all evidence of disease while minimizing treatment-related side effects and unnecessary therapies. This initial management, if successful, should result in decreasing local or distant recurrence as well as disease-specific mortality. While certainly not a new concept, the last several years have seen a renewed interest in a risk-adapted approach to the management of thyroid cancer in which the extent and intensity of initial therapy is tailored according to individualized risk estimates of recurrence and mortality. Following thyroid surgery (either total thyroidectomy or hemi-thyroidectomy), patients continue a risk-adapted approach to ongoing thyroid cancer management based on standardized clinicopathologic factors that predict the risk of recurrence and/or mortality. In this approach, the risks and benefits of potential additional therapies are balanced against the specific risks of recurrence, mortality, and response to therapy for individual patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mazzaferri EL (2007) Management of low-risk differentiated thyroid cancer. Endocr Pract 13(5):498–512

    PubMed  Google Scholar 

  2. Tuttle RM (2008) Risk-adapted management of thyroid cancer. Endocr Pract 14(6):764–774

    PubMed  Google Scholar 

  3. Hay ID (2006) Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 94(8):692–700

    Article  PubMed  Google Scholar 

  4. Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214

    Article  PubMed  Google Scholar 

  5. Tuttle RM (2010) National comprehensive cancer network, clinical practice guidelines in oncology, thyroid cancer. http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf. Cited 8 Apr 2010

  6. Grebe SK, Hay ID (1996) Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 5(1):43–63

    PubMed  CAS  Google Scholar 

  7. Mazzaferri EL, Kloos RT (2001) Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86(4):1447–1463

    Article  PubMed  CAS  Google Scholar 

  8. Sherman SI, Brierley JD, Sperling M et al (1998) Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83(5):1012–1021

    Article  PubMed  CAS  Google Scholar 

  9. Lang BH, Lo CY, Chan WF et al (2007) Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 245(3):366–378

    Article  PubMed  Google Scholar 

  10. Tuttle RM, Lopez N, Leboeuf R et al (2010) Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 20(3):257–263

    Article  PubMed  CAS  Google Scholar 

  11. Baek SK, Jung KY, Kang SM et al (2010) Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid 20(2):147–152

    Article  PubMed  Google Scholar 

  12. Orlov S, Orlov D, Shaytzag M et al (2009) Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 31(6):782–788

    Article  PubMed  Google Scholar 

  13. Bilimoria KY, Bentrem DJ, Ko CY et al (2007) Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246(3):375–381, discussion 381–384

    Article  PubMed  Google Scholar 

  14. van Heerden JA, Hay ID, Goellner JR et al (1992) Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 112(6):1130–1136, discussion 1136–1138

    PubMed  Google Scholar 

  15. Liu J, Singh B, Tallini G et al (2006) Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 107(6):1255–1264

    Article  PubMed  Google Scholar 

  16. Fagin JA, Mitsiades N (2008) Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 22(6):955–969

    Article  PubMed  CAS  Google Scholar 

  17. Nikiforova MN, Nikiforov YE (2008) Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8(1):83–95

    Article  PubMed  CAS  Google Scholar 

  18. Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90(12):6373–6379

    Article  PubMed  CAS  Google Scholar 

  19. Nikiforova MN, Kimura ET, Gandhi M et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88(11):5399–5404

    Article  PubMed  CAS  Google Scholar 

  20. Robbins RJ, Srivastava S, Shaha A et al (2004) Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 89(12):6010–6016

    Article  PubMed  CAS  Google Scholar 

  21. Pacini F, Molinaro E, Castagna MG et al (2003) Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88(8):3668–3673

    Article  PubMed  CAS  Google Scholar 

  22. Eustatia-Rutten CF, Smit JW, Romijn JA et al (2004) Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 61(1):61–74

    Article  CAS  Google Scholar 

  23. Spencer CA (2004) Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 89(8):3702–3704

    Article  PubMed  CAS  Google Scholar 

  24. Larson SM, Robbins R (2002) Positron emission tomography in thyroid cancer management. Semin Roentgenol 37(2):169–174

    Article  PubMed  Google Scholar 

  25. Wang W, Larson SM, Tuttle RM et al (2001) Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11(12):1169–1175

    Article  PubMed  CAS  Google Scholar 

  26. Robbins RJ, Wan Q, Grewal RK et al (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18 F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91(2):498–505

    Article  PubMed  CAS  Google Scholar 

  27. Smallridge RC, Meek SE, Morgan MA et al (2007) Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 92(1):82–87

    Article  PubMed  CAS  Google Scholar 

  28. Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154(6):787–803

    Article  PubMed  CAS  Google Scholar 

  29. Tuttle RM, Tala H, Shah J et al (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. Thyroid 20(12):1341–1349

    Article  PubMed  CAS  Google Scholar 

  30. McGriff NJ, Csako G, Gourgiotis L et al (2002) Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34(7–8):554–564

    Article  PubMed  CAS  Google Scholar 

  31. Biondi B, Filetti S, Schlumberger M (2005) Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1(1):32–40

    Article  PubMed  CAS  Google Scholar 

  32. Biondi B, Cooper DS (2010) Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 20(2):135–146

    Article  PubMed  CAS  Google Scholar 

  33. Dean DS, Hay ID (2000) Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 7(3):229–239

    PubMed  CAS  Google Scholar 

  34. Byar DP, Green SB, Dor P et al (1979) A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 15(8):1033–1041

    PubMed  CAS  Google Scholar 

  35. Hay ID, Grant CS, Taylor WF et al (1987) Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102(6):1088–1095

    PubMed  CAS  Google Scholar 

  36. Cady B, Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104(6):947–953

    PubMed  CAS  Google Scholar 

  37. Hay ID, Bergstralh EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114(6):1050–1057, discussion 1057–1058

    PubMed  CAS  Google Scholar 

  38. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97(5):418–428

    Article  PubMed  CAS  Google Scholar 

  39. Shaha AR, Loree TR, Shah JP (1995) Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118(6):1131–1136, discussion 1136–1138

    Article  PubMed  CAS  Google Scholar 

  40. Greene FL, Page DL, Fleming ID (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New York

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Endocrinology Service, Memorial Sloan-Kettering Cancer Center, Zuckerman Building, 1275 York Avenue, New York, NY, 10021, USA

    Geneviève Rondeau M.D. & Robert Michael Tuttle M.D.

Authors
  1. Geneviève Rondeau M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Michael Tuttle M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Michael Tuttle M.D. .

Editor information

Editors and Affiliations

  1. Chairman, Department of Surgery, University Hospital Basel, Spitalstr. 21, Basel, 4031, Switzerland

    Daniel Oertli

  2. Yale-New Haven Hospital, Department of Surgery, Yale University School of Medicine, Cedar Street 330FMB 102, New Haven, CT, 06520-8062, USA

    Robert Udelsman

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rondeau, G., Tuttle, R.M. (2012). Postoperative Surveillance for Recurrent Malignant Disease. In: Oertli, D., Udelsman, R. (eds) Surgery of the Thyroid and Parathyroid Glands. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-23459-0_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-23459-0_24

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-23458-3

  • Online ISBN: 978-3-642-23459-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation